The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers. Ultimately, our goal is to make cancer screening easy and effective so that we can detect cancer earlier when it's most treatable." "Our partnership with Guardant Health adds next-generation sequencing diagnostics that can potentially transform cancer care in MENA bringing hope to patients facing this challenging journey. We are excited to partner with Guardant Health, as their offering can help patients at all stages of the disease – from screening to monitoring cancer recurrence to guiding treatment decisions. doi:10.1200/GO.21.00415SOURCE Guardant Health

Source: The North Africa Journal January 08, 2024 07:30 UTC